Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Rutger‐Jan Swijnenburg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3980-4634; OpenAlex author ID A5022156712. Sources: OpenAlex.

Their work

Papers
25 (first author 1, last author 7)
Trials
0
Grants
0
Labs led
2
Collaborators
77
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 4 papers · 2019: 6 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 25

  1. 18F-Prostate-Specific Membrane Antigen PET/CT imaging for potentially resectable pancreatic cancer (PANSCAN-2): a phase I/II study. Last author DOI 10.1186/s40644-025-00822-y↗
  2. Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer. Co-author DOI 10.1016/j.jlb.2024.100152↗
  3. Unlocking the diagnostic power of plasma extracellular vesicle miR-200 family in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03090-z↗
  4. Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy: A Single-Center Experience. Co-author DOI 10.1245/s10434-024-15591-4↗
  5. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons' Perspectives on Curren… Co-author DOI 10.3390/cancers15030652↗
  6. Novel Strategies to Address Critical Challenges in Pancreatic Cancer. First author DOI 10.3390/cancers14174115↗
  7. Prostate-Specific Membrane Antigen Targeted Pet/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer. Co-author DOI 10.3390/cancers14246209↗
  8. Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Co-author DOI 10.3390/cancers13236088↗
  9. Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13246164↗
  10. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Last author DOI 10.1038/s41598-020-73242-6↗
  11. Elevated CEA and CA19-9 serum levels independently predict advanced pancreatic cancer at diagnosis. Co-author DOI 10.1080/1354750x.2020.1725786↗
  12. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Last author DOI 10.1002/bjs.11115↗
  13. Author response to: Resection margin status in pancreatic cancer surgery: is it really less important than the N status? Last author DOI 10.1002/bjs.11355↗
  14. Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). Co-author DOI 10.1016/j.eclinm.2019.10.013↗
  15. Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. Co-author DOI 10.1016/j.ejso.2019.06.004↗
  16. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.11.008↗
  17. A Prospective Clinical Trial to Determine the Effect of Intraoperative Ultrasound on Surgical Strategy and Resection Outcome in Patients with Pancreatic Cancer. Co-author DOI 10.1016/j.ultrasmedbio.2019.04.020↗
  18. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000001075↗
  19. Development and Preclinical Validation of a Cysteine Knottin Peptide Targeting Integrin αvβ6 for Near-infrared Fluorescent-guided Surgery in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2491↗
  20. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Co-author DOI 10.1245/s10434-018-6453-2↗
  21. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infr… Co-author DOI 10.1245/s10434-018-6655-7↗
  22. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer. Co-author DOI 10.1007/s10689-016-9915-3↗
  23. Targeted next-generation sequencing of FNA-derived DNA in pancreatic cancer. Co-author DOI 10.1136/jclinpath-2016-203928↗
  24. Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.18232↗
  25. Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Co-author DOI 10.1007/s11307-016-0959-4↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alexander L. Vahrmeijer · 18 shared papers, 2016–2023 · strength 1.68
  2. Bert A. Bonsing · 15 shared papers, 2016–2021 · strength 1.26
  3. J. Sven D. Mieog · 13 shared papers, 2016–2023 · strength 1.22
  4. Geert Kazemier M · 5 shared papers, 2022–2025 · strength 0.96
  5. Jisce R. Puik · 4 shared papers, 2022–2025 · strength 0.79
  6. Elisa Giovannetti · 4 shared papers, 2022–2025 · strength 0.79
  7. Willemieke S. F. J. Tummers · 8 shared papers, 2016–2019 · strength 0.67
  8. Johanna W. Wilmink · 4 shared papers, 2020–2025 · strength 0.67
  9. Marc G. Besselink · 4 shared papers, 2020–2024 · strength 0.59
  10. Floris A. Vuijk · 4 shared papers, 2020–2022 · strength 0.48
  11. Thomas T. Poels · 2 shared papers, 2021–2025 · strength 0.40
  12. Jesse V. Groen · 3 shared papers, 2019–2020 · strength 0.35
  13. Joanne Verheij · 2 shared papers, 2020–2025 · strength 0.33
  14. Sanjiv Sam Gambhir · 4 shared papers, 2018–2019 · strength 0.33
  15. Annalisa Comandatore · 2 shared papers, 2024 · strength 0.33
  16. Luca Morelli · 2 shared papers, 2024 · strength 0.33
  17. Adam Enver Frampton · 2 shared papers, 2024 · strength 0.33
  18. Babs G. Sibinga Mulder · 4 shared papers, 2017–2019 · strength 0.33
  19. Peter J.K. Kuppen · 4 shared papers, 2016–2021 · strength 0.32
  20. Cornelis F.M. Sier · 4 shared papers, 2016–2021 · strength 0.32
  21. Casper H.J. van Eijck · 3 shared papers, 2017–2019 · strength 0.23
  22. Lysanne D. A. N. de Muynck · 2 shared papers, 2020–2023 · strength 0.23
  23. Jürgen K. Willmann · 2 shared papers, 2018 · strength 0.18
  24. Hans Morreau · 3 shared papers, 2016–2017 · strength 0.18
  25. Mustafa Suker · 2 shared papers, 2019 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.